DMYD B — Diamyd Medical AB Income Statement
0.000.00%
Last trade - 00:00- SEK1.45bn
- SEK1.22bn
- SEK0.13m
Annual income statement for Diamyd Medical AB, fiscal year end - August 31st, SEK millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.253 | 0.454 | 0.546 | 0.13 | 0.13 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 86.1 | 119 | 121 | 156 | 184 |
| Operating Profit | -85.9 | -118 | -121 | -156 | -184 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 60 | -104 | -116 | -152 | -170 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 60 | -104 | -116 | -152 | -170 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 60 | -104 | -116 | -152 | -170 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 60 | -104 | -116 | -152 | -170 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.836 | -1.31 | -1.48 | -1.49 | -1.5 |
| Dividends per Share |